By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: Company's Biosimilar Candidate To Humira® Accepted For EMA And FDA Regulatory Review 1/18/2017 7:43:11 AM
Humana (HUM) And Boehringer Ingelheim Report New Findings Suggesting Strategies For Improving COPD Medication Adherence 1/9/2017 10:04:36 AM
Boehringer Ingelheim to Sell Off Animal Health Products to Enable Sanofi (SNY) Swap 12/29/2016 7:57:00 AM
Boehringer Ingelheim And Eli Lilly (LLY) Welcome New Recommendation For Jardiance (Empagliflozin) Tablets In Updated American Diabetes Association's 2017 Standards 12/19/2016 9:50:25 AM
Boehringer Ingelheim Release: CHMP Adopts A Positive Opinion Acknowledging That Jardiance Reduces The Risk Of CV Death 12/16/2016 11:29:17 AM
Boehringer Ingelheim Release: Nintedanib Granted Orphan Drug Designation For Treatment Of Mesothelioma 12/15/2016 8:24:51 AM
Boehringer Ingelheim Release: Limited Improvement In EGFR Testing Rates Observed In New Survey With Approximately One In Five Advanced Lung Cancer Patients Still At Risk Of Missing Out On Targeted Therapy 12/7/2016 11:01:25 AM
Boehringer Ingelheim HCP Survey: Nearly 20% Of Newly Diagnosed Lung Cancer Patients Tested For EGFR Mutations At Risk Of Missing Out On Personalised Treatments For Their Disease 12/7/2016 9:50:21 AM
Boehringer Ingelheim Release: Clinically Meaningful Data For Oral Nintedanib In Mesothelioma Presented At World Conference On Lung Cancer 12/7/2016 7:56:04 AM
Boehringer Ingelheim Release: FDA Approves Jardiance (Empagliflozin) Tablets To Reduce The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes And Established Cardiovascular Disease 12/6/2016 11:06:36 AM